SUO 2024 Videos

Primary Chemo Ablation with UGN-102 for Recurrent Low Grade Bladder Cancer in the ENVISION Trial - Sandip Prasad

What Everyone’s Talking About: Highlights from SUO 2024 - Amy Luckenbaugh

Adjuvant Systemic Therapies for Urothelial Carcinoma: Current Evidence and Future Directions - Jean Hoffman-Censits

SunRISe-5 Trial Tests TAR-200 for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Sima Porten

Serial ctDNA Testing Identifies Bladder Cancer Patients Who May Avoid Adjuvant Therapy - Joaquim Bellmunt

Consolidative Local Therapy in Metastatic Bladder Cancer After Systemic Treatment Response - Fed Ghali

Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer - Jacqueline Brown

Smoking Cessation as a Precision Cancer Care Intervention in Urologic Oncology - Richard Matulewicz

FGFR3 Inhibition in Urothelial Cancer Advances with Erdafitinib and TAR-210 Trials - Gopa Iyer

AI in Renal Mass Classification: Current Challenges and Future Potential - Nicholas Kavoussi

Combining Radioligand Therapy with Cabozantinib and Nivolumab in Advanced Clear Cell RCC - Eric Jonasch

Preventing and Managing Complications of Radical Cystectomy - Hadley Wyre

Opevesostat Trial in mCRPC: Targeting Androgen Biosynthesis Upstream for Improved Outcomes - Christian Gratzke

Advances in Muscle-Invasive Bladder Cancer: Systemic Therapies and Surgical Innovations - Jen-Jane Liu

ProstACT GLOBAL Trial: Combining PSMA-Targeted Therapy with ARPIs and Docetaxel - Oliver Sartor

Combining EZH2 and AR Targeting in Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal

Phase II Trial Explores Gemcitabine Plus BCG for BCG-Exposed Bladder Cancer - Eugene Pietzak & Gal Wald

Moving Beyond Single Arm Trials in BCG Unresponsive Cancer Care - Joshua Meeks

Safety and Tolerability of TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer in SUNRISE-1 - Siamak Daneshmand

Sexual Dysfunction After Radical Cystectomy - Trinity Bivalacqua

CORE-008 Cohort B Tests Cretostimogene’s Efficacy in High-Risk, Non-BCG-Responsive Disease - Trinity Bivalacqua

CORE-008 Cohort A Tests Oncolytic Immunotherapy in BCG-Naive High-Risk Bladder Cancer - Trinity Bivalacqua

Expanded Access Program Provides Early Cretostimogene Therapy for Bladder Cancer - Sarah Psutka

Utilizing Telehealth to Improve Access of Care of Patients with Bladder Cancer - Tracey Krupski

Integrating Genomic Testing with MRI Enhances Stratification of Surveillance Patients - Eric Kim & Mark Sultan

Advancing Treatment for BCG-Unresponsive Bladder Cancer - Eugene Pietzak

PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson

Emerging Neoadjuvant Combinations for Muscle-Invasive Bladder Cancer - Mamta Parikh

BCG Unresponsive Bladder Cancer in 2024 - Ashish Kamat

BOND-003 Trial Results in BCG Unresponsive Non-muscle Invasive Bladder Cancer - Mark Tyson